HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution

References

• UNAIDS, WHO UNAIDS data 2020. https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf. 2020. [Accessed 15 02 2022)].
   Google Scholar
• WHO, Global hepatitis report 2017, (https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf; WHO. Accessed 15 02 2022).
   Google Scholar
• Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016 Jul;16(7):797–808.
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl):S6–9.
   PubMed Web of Science ®Google Scholar
• Frederick T, Burian P, Terrault N, et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the women’s interagency HIV study (WIHS). AIDS Patient Care STDS. 2009 Nov;23(11):915–923.
   PubMed Web of Science ®Google Scholar
• Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study. HIV Med. 2013;14:195–207.
   PubMed Web of Science ®Google Scholar
• Chen T-Y, Ding EL, Seage Iii GR, et al. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis an off Publ Infect Dis Soc Am. 2009 Nov;49(10):1605–1615.
   PubMed Web of Science ®Google Scholar
• Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014 May;28(8):1181–1191.
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22:1979–1991.
   PubMed Web of Science ®Google Scholar
• Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193–1199.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007 Oct;21(16):2209–2216.
   PubMed Web of Science ®Google Scholar
• Sherman KE, Rockstroh J, Thomas D. Human immunodeficiency virus and liver disease: an update. Hepatology. 2015;62:1871–1882.
   PubMed Web of Science ®Google Scholar
• Pérez-Olmeda M, Núñez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003 May;17(7):1023–1028.
   PubMed Web of Science ®Google Scholar
• Collins LF, Chan A, Zheng J, et al. Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection. Open Forum Infect Dis. 2018;5. 10.1093/ofid/ofx264.
   Google Scholar
• Ishida H, Ishihara A, Tanaka S, et al. Favorable outcome with direct-acting antiviral treatment in hepatitis C patients coinfected with HIV. Hepatol Res. 2019 Sep;49(9):1076–1082.
   PubMed Web of Science ®Google Scholar
• Milazzo L, Lai A, Calvi E, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med. 2017 Apr;18(4):284–291.
   PubMed Web of Science ®Google Scholar
• Sikavi C, Chen PH, Lee AD, et al. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: no longer a difficult-to-treat population. Hepatology. 2018;67(3):847–857.
   PubMed Web of Science ®Google Scholar
• Piroth L, Wittkop L, Lacombe K, et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients – French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017;67(1):23–31.Internet].
   PubMed Web of Science ®Google Scholar
• Berenguer J, Gil-Martin Á, Jarrin I, et al. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology. 2018;68(1):32–47.
   PubMed Web of Science ®Google Scholar
• Rossi C, Young J, Martel-Laferrière V, et al. Direct-acting antiviral treatment failure among hepatitis C and HIV-coinfected patients in clinical care. Open Forum Infect Dis. 2019 Mar;6(3):ofz055.
   PubMed Web of Science ®Google Scholar
• Neukam K, Morano-Amado LE, Rivero-Juárez A, et al. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. HIV Clin Trials. 2017 May;18(3):126–134.
   PubMed Web of Science ®Google Scholar
• Arias A, Aguilera A, Soriano V, et al. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir Ther. 2017;22:307–312.
   PubMed Web of Science ®Google Scholar
• Boesecke C, Ingiliz P, Berger F, et al. Liver cirrhosis as a risk factor for direct-acting antiviral therapy failure in real-life hepatitis C virus/human immunodeficiency virus coinfection. Open Forum Infect Dis. 2017;4(3):ofx158.
   PubMed Web of Science ®Google Scholar
• López-Cortés LF, Trujillo-Rodríguez M, Báez-Palomo A, et al. Eradication of hepatitis C virus (HCV) reduces immune activation, microbial translocation, and the HIV DNA level in HIV/HCV-coinfected patients. J Infect Dis. 2018 Jul;218(4):624–632.
   PubMed Web of Science ®Google Scholar
• Saracino A, Bruno G, Scudeller L, et al. CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2016 Aug;81:94–99.
   Web of Science ®Google Scholar
• Milazzo L, Foschi A, Mazzali C, et al. Short communication: impact of hepatitis C viral clearance on CD4 + T-lymphocyte course in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. AIDS Res Hum Retroviruses. 2012;28:989–993.
   PubMedGoogle Scholar
• Dazley J, Sison R, Slim J. Long-term consequences of hepatitis C viral clearance on the CD4 (+) T cell lymphocyte course in HIV/HCV coinfected patients. AIDS Res Treat. 2015;2015:687629.
   PubMedGoogle Scholar
• Najafi Fard S, Schietroma I, Corano Scheri G, et al. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. Clin Res Hepatol Gastroenterol. 2018;42:319–329.
   PubMedGoogle Scholar
• Emmanuel B, El-Kamary SS, Magder LS, et al. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic hepatitis C patients. Hepatol Int. 2019;13:270–276.
   PubMedGoogle Scholar
• Lim JK, Flamm SL, Singh S, et al. American gastroenterological association institute guideline on the role of elastography in the evaluation of liver fibrosis. Gastroenterology. 2017May1;Internet]. ;152(6):1536–1543.
   PubMed Web of Science ®Google Scholar
• Lin Z-H, Xin Y-N, Dong Q-J, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011 Mar;53(3):726–736.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006Jun1;Internet]. ;43(6):1317–1325.
   PubMed Web of Science ®Google Scholar
• Shrivastava S, Bhatta M, Ward H, et al. Multitarget direct-acting antiviral therapy is associated with superior immunologic recovery in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatol Commun. 2018Dec1;Internet]. ;2(12):1451–1466.
   PubMed Web of Science ®Google Scholar